Modern Healthcare Technology Holdings (HKSE:00919) ROE % Adjusted to Book Value: -19.40% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Modern Healthcare Technology Holdings ROE % Adjusted to Book Value?

Modern Healthcare Technology Holdings HKSE:00919 -2.53% ROE % Adjusted to Book Value is -19.40% as of Mar. 2026. The stock has 3 warning signs investors should review.

Modern Healthcare Technology Holdings's ROE % for the quarter that ended in Mar. 2026 was -8.73%. Modern Healthcare Technology Holdings's PB Ratio for the quarter that ended in Mar. 2026 was 0.45. Modern Healthcare Technology Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -19.40%.


Modern Healthcare Technology Holdings ROE % Adjusted to Book Value Related Terms


Modern Healthcare Technology Holdings ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Modern Healthcare Technology Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modern Healthcare Technology Holdings ROE % Adjusted to Book Value Chart

Modern Healthcare Technology Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.16 -13.28 -10.93 -7.50 -2.11

Modern Healthcare Technology Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.64 -33.75 34.58 19.69 -19.40

HKSE:00919 vs ROL, SCI, HRB: ROE % Adjusted to Book Value Comparison

For the Personal Services subindustry, Modern Healthcare Technology Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modern Healthcare Technology Holdings ROE % Adjusted to Book Value vs Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, Modern Healthcare Technology Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Modern Healthcare Technology Holdings's ROE % Adjusted to Book Value falls into.



Modern Healthcare Technology Holdings ROE % Adjusted to Book Value Calculation

Modern Healthcare Technology Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-0.95% / 0.45
=-2.11%

Modern Healthcare Technology Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.73% / 0.45
=-19.40%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -19.40% mean?
Modern Healthcare Technology Holdings (HKSE:00919) has a ROE % Adjusted to Book Value of -19.40% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Modern Healthcare Technology Holdings and its competitors.
Is Modern Healthcare Technology Holdings' ROE % Adjusted to Book Value too high?
Modern Healthcare Technology Holdings' current ROE % Adjusted to Book Value is -19.40%.
How does Modern Healthcare Technology Holdings' ROE % Adjusted to Book Value compare to ROL and SCI?
Modern Healthcare Technology Holdings' ROE % Adjusted to Book Value of -19.40% can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Personal Services company?
A good ROE % Adjusted to Book Value depends on the Personal Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Modern Healthcare Technology Holdings and its competitors. Modern Healthcare Technology Holdings's current ROE % Adjusted to Book Value is -19.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Healthcare Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Modern Healthcare Technology Holdings (HKSE:00919) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.09, compared to a current price of HK$0.08 — trading 14.4% below its estimated fair value. The current ROE % Adjusted to Book Value is -19.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Modern Healthcare Technology Holdings (HKSE:00919), the current ROE % Adjusted to Book Value is -19.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modern Healthcare Technology Holdings Business Description

Other Exchanges M3L:Germany
Address 9 Kai Cheung Road, Workshops Nos. 66-68, 6th Floor, Sino Industrial Plaza, Kowloon Bay, Kowloon, Hong Kong, HKG
Modern Healthcare Technology Holdings Ltd is an investment holding company. The company's operating segment includes Beauty and wellness services and Skincare and wellness products. The company generates maximum revenue from Beauty and wellness services segment. The Beauty and Wellness Services segment of the company is engaged in the provision of beauty and wellness services which provides a wide range of health and beauty services, covering skin care, slimming, massage, spa, hair care, manicure, hair removal, makeup, joint care, and privacy care. Geographically, the company derives the maximum of its revenue from Hong Kong and has a presence in Singapore; China, and Australia.